April 20, 1999CirculationOpen Access

Kallidin- and Bradykinin-Degrading Pathways in Human Heart

View Full Paper

Ask AI

Bookmark

Population

Cardiac membranes from left ventricles of normal and failing human hearts.

Comparison

Incubation with kallidin or bradykinin in the… vs Normal vs. failing hearts; presence vs. absence…

Design

Preclinical

Authors

JKJorma KokkonenTampere University Hospital AKAntti KuoppalaHigher Colleges of Technology JSJuhani SaarinenGlykos (Finland)

Discussion

Member takes

Implication

NEP predominates in cardiac bradykinin inactivation; leaves open whether NEP inhibition is cardioprotective in humans.

Structured PICO

Population

Cardiac membranes from left ventricles of normal (n=5) and failing (n=10) human hearts (end-stage congestive heart failure due to coronary heart disease or idiopathic dilated cardiomyopathy).

Intervention

Incubation with kallidin (KD) or bradykinin (BK) in the presence or absence of enzyme inhibitors

Comparator

Normal vs. failing hearts; presence vs. absence of enzyme inhibitors

Outcome

Enzymes responsible for kinin metabolism and their activitiessurrogate

In human cardiac membranes, bradykinin inactivation is primarily mediated by neutral endopeptidase (NEP) rather than ACE, suggesting NEP inhibition could be cardioprotective by elevating local bradykinin concentrations.

Cite This Study

Kokkonen et al. (1999) studied this question.

synapsesocial.com/papers/6a910f8855de849fda7a7be4 https://doi.org/10.1161/01.cir.99.15.1984

Topics

Heart failure HFrEF treatment

View Full Paper

Ask AI

Bookmark

Kallidin- and Bradykinin-Degrading Pathways in Human Heart

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Kallidin- and Bradykinin-Degrading Pathways in Human Heart

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider